Phase 1 Study of BDC-1001 as a Single Agent and in Combination with Pembrolizumab in Patients with Advanced and HER2-Expressing Solid Tumors
A First-in-Human Study Using BDC-1001 in Advanced and HER2-Expressing Solid Tumors
Sponsor: Bolt Biotherapeutics, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAS8693
U.S. Govt. ID: NCT04278144
Contact: Research Nurse Navigator: 212-342-5162 /
Additional Study Information: The purpose of this study is to learn about the study drug BDC-1001 in patients with HER2-expressing tumors. Researchers will be studying the use of BDC-1001 alone as well as in combination with Pembrolizaumab. This study will help researchers learn if the study drug can help with HER2-expressing tumors and how people respond to the drug. The researchers of this study will be looking at the safety, efficiency, and tolerability of BDC-1001, as well as how the body absorbs, breaks down, and removes the drug in patients with advanced HER2-expressing solid tumors. This research study will be the first time BDC-1001 will be given to people. The BDC-1001 study drug is expected to stimulate the immune system and target and attack HER2-expressing tumors. Cancers include: Breast cancer, esophageal cancer, ovarian cancer, lung cancer, pancreatic cancer, and stomach cancer.
This study is closed
Richard Carvajal, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Have you been diagnosed with a HER2-expressing tumor? Yes No
Are you willing to provide blood samples? Yes No
Have you had major surgery in the past 4 weeks? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator